Codexis Inc (CDXS) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Codexis Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Codexis Inc 's ROA in the second quarter of 2026?
Codexis Inc recorded a cumulative net loss of $-31 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -20.81%.
However, within the Basic Materials sector 222 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3523, from total ROA ranking in the first quarter of 2026 at 4316.
Codexis: Cultivating Talent Through Strategic Equity Inducement in the Biotechnology SectorIn a landscape dominated by rapid advancements and intense competition, biotechnology companies are increasingly turning to innovative strategies for attracting and retaining top talent. Codexis, Inc. (NASDAQ: CDXS), a prominent player in the realm of enzymatic solutions for the manufacturing of therapeutics, stands at the forefront of this trend. With a solidified commitment to growth and innovation, Codexis recently announced a series of progressive equity inducement grants aimed at bolstering its talent acquisition efforts as it charts its course through an evolving market.In a noteworthy move earlier this year, on January 10, 2025, Codexis revealed it had obtained approval from its Compensation Committee to offer equity grants to two new employees. This move was part of the company’s 2024 Inducement Plan and included options to purchase a total of 23,000 shares of Codexis common stock, complemented by 11,500 restricted stock units (RSUs). This strategy is a clear demonstration of Codexis’s ambitious goal to create competitive compensation packages that not only attract but also retain the high-caliber professionals required to propel its growth trajectory.
Codexis Strengthens Talent Acquisition Strategy with Strategic Equity Inducement Grants Amidst Continued GrowthIn a strategic bid to enhance its talent acquisition efforts and solidify its position in the competitive biotechnology sector, Codexis, Inc. (NASDAQ: CDXS), a frontrunner in enzymatic solutions for efficient therapeutics manufacturing, recently announced significant equity inducement grants. This initiative, embodying the firm’s commitment to attracting and retaining top-tier talent, is integral as Codexis navigates its path forward with ambitious growth plans.On January 10, 2025, Codexis revealed that its Compensation Committee had approved equity grants for two newly hired employees as part of the company s 2024 Inducement Plan. The inducement awards encompass options to purchase a total of 23,000 shares of Codexis common stock, along with 11,500 restricted stock units (RSUs). This move not only reflects the firm’s proactive approach to enhancing employee compensation packages but also underscores its goal of fostering a robust workforce equipped to drive innovation and growth.
Unlocking Growth: Codexis Enhances Financial Resilience and Human Capital Amid Market ChallengesIn an era marked by uncertainty in the biotech sector, Codexis Inc. a prominent enzyme engineering company based in Redwood City, California, is taking strategic steps to bolster its financial health and enhance its talent pool. Recently, the company announced a significant capital injection of $31 million through an at-the-market (ATM) offering, extending its cash runway into 2027. Coupled with its commitment to attract top talent via innovative employment inducement grants, Codexis appears poised to navigate these turbulent waters and maintain its trajectory of growth. Financial Fortification Through Capital RaiseCodexis s recent capital raise reflects a proactive approach to securing its ongoing operational needs and fueling future initiatives. The $31 million garnered through the ATM strategy allows the company not only to stabilize its balance sheet but also to consider strategic investments in research and development, partnerships, and expansion efforts. This infusion of cash is particularly timely given the current climate in biotechnology, where many firms face mounting pressures due to fluctuating market conditions and increased competition.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
